Advocacy and reform are central to Bogart’s Legacy. Research preserves and expands knowledge; reform asks what should change when that knowledge reveals gaps in care, monitoring, communication, or treatment safeguards.
Our goal is not to eliminate clinical judgment. It is to help ensure that veterinarians and families have clearer standards to guide difficult decisions before a crisis occurs.
Many chemotherapy drugs commonly used in veterinary oncology were developed and approved for human patients and are prescribed to dogs off-label. Only a limited number of cancer drugs have FDA approval specifically for canine use.
Off-label treatment can be entirely appropriate. But when powerful cytotoxic drugs are used in dogs, clear guidance around dosing, monitoring, toxicity, supportive care, and treatment modification becomes especially important.
Every dog is different. Bogart’s Legacy is not advocating for rigid treatment schedules that ignore age, disease, genetics, organ function, prior toxicity, or individual response.
What is needed are stronger evidence-based guardrails around the decisions that surround treatment: when to hold a dose, when to reduce or modify treatment, when supportive care should begin, when monitoring should intensify, and when significant toxicity requires a change in course.
Clinical judgment should operate within meaningful safeguards — not substitute for them.
An adverse event does not become less important because it is uncommon.
When a treatment carries the potential for serious organ injury or other significant toxicity, veterinarians and families should know what to monitor, what warning signs matter, and what response is appropriate if those signs appear.
Families deserve a clear and complete discussion of material risks, expected benefits, reasonable alternatives, monitoring requirements, and foreseeable complications — before treatment begins and again when circumstances materially change.
More consistent clinical guidance for dosing, monitoring, toxicity assessment, and escalation of care.
Evidence-based criteria to help guide when treatment should proceed, pause, change, or end.
Clearer expectations for symptom control, hydration, nutritional support, hepatoprotection where appropriate, and other supportive measures associated with intensive treatment.
Recognition that nutritional status and hydration are active components of patient care and should be assessed and supported throughout treatment.
Drug- and risk-appropriate monitoring of blood counts, organ function, clinical status, and emerging toxicity.
Consideration of MDR1/ABCB1 and other clinically relevant genetic information when it may affect drug exposure, toxicity, treatment response, or supportive-care decisions.
Concrete, citable proposals that veterinary professionals, practices, researchers, and professional organizations can evaluate, criticize, refine, and potentially adopt.
Using published evidence, documented cases, original research, surveys, and clinical experience to identify where current practice can be strengthened.
During the investigation of Bogart’s treatment, important questions emerged about how treatment-related toxicity is recognized, how decisions to continue or hold chemotherapy are made, when supportive care should begin, and how risks are communicated to families.
Bogart had peripheral T-cell lymphoma and was being treated with CCNU. During treatment, he developed severe Grade 4 liver injury attributed to the drug. Five days later, he died.
His lymphoma was terminal, and no one can know with certainty whether a different course would have changed the ultimate outcome. But that uncertainty does not erase the questions raised by his treatment. The standards governing continuation of therapy, toxicity response, supportive care, monitoring, and informed consent deserved to be clearer.
That is the problem Bogart’s Legacy intends to examine.
What reform could look likeBogart’s Legacy is working toward practical, evidence-based proposals that can be examined by veterinary professionals and researchers.
Those proposals will draw from published literature, original research, documented clinical cases, owner experience, and professional review. As the underlying papers and research mature, recommendations will become more specific, more heavily sourced, and more suitable for formal evaluation.
The objective is not to dictate medicine from outside the profession.
It is to identify preventable gaps, ask difficult questions, and help develop safeguards strong enough to matter before another family is facing a crisis.
If you are a veterinary professional, researcher, breeder, or owner with relevant experience, evidence, or a documented case, Bogart’s Legacy welcomes serious contributions to this work.
Get in touch